Exelixis, Inc. (EXEL) entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx (cabozantinib).Cabometyx is Exelixis’ lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla’s abbreviated new drug application (ANDA).The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla’s ANDA for a 60 mg cabozantinib do ...